This database contains 429 studies, archived under the term: "USA"
Click here to filter this large number of results.
Public-private partnerships improve health outcomes in individuals with early stage Alzheimer’s disease
Purpose: In a collaborative effort between the Missouri Department of Health, Area Agencies on Aging (AAA), Alzheimer Association, and academic researchers, we tested whether early dementia detection and comprehensive care consultations would improve health outcomes in care receivers (CRs) and their family caregivers (FCGs), therefore addressing an important public health concern.; Participants and Methods: A […]
Preserving Identity and Planning for Advance Care (PIPAC): preliminary outcomes from a patient-centered intervention for individuals with mild dementia
Hilgeman, Michelle M.,
Allen, Rebecca S.,
Snow, A. Lynn,
Durkin, Daniel W.,
DeCoster, Jamie,
Burgio, Louis D.
Objectives: The purpose of this pilot study was to conduct limited-efficacy testing of the newly developed Preserving Identity and Planning for Advance Care (PIPAC) intervention on self-reported and proxy-reported emotional and health-related outcomes of individuals in the early stages of dementia.; Method: A two-group comparison design was implemented. Blocked randomization was used to assign individuals […]
Life enhancing activities for family caregivers of people with frontotemporal dementia
Dowling, Glenna A.,
Merrilees, Jennifer,
Mastick, Judy,
Chang, Vickie Y.,
Hubbard, Erin,
Moskowitz, Judith Tedlie
Aberrant psychological and behavioral symptoms are common in patients with dementia. These symptoms have negative consequences for family caregivers, causing stress and burden. Frontotemporal dementia (FTD) symptoms cause more pronounced stress and burden on caregivers than those associated with Alzheimer dementia. In this randomized, attention control pilot study, we delivered 5-weekly, one-on-one, positive affect intervention […]
Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD
Silverman, Daniel H. S.,
Geist, Cheri L.,
Kenna, Heather A.,
Williams, Katherine,
Wroolie, Tonita,
Powers, Bevin,
Brooks, John,
Rasgon, Natalie L.
Differential cerebral metabolic effects of various hormone therapy formulations, and their associations with cognitive status, remain to be established. The principal aim of the current study was to assess relationships between regional cerebral metabolism and estrogen-based hormone therapies. Postmenopausal women (n=53) at elevated risk for Alzheimer’s disease (AD) were on estrogen-containing hormone therapy for at […]
Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease
Siemers, Eric R.,
Friedrich, Stuart,
Dean, Robert A.,
Gonzales, Celedon R.,
Farlow, Martin R.,
Paul, Steven M.,
Demattos, Ronald B.
Objectives: Active and passive immunization strategies have been suggested as possible options for the treatment of Alzheimer disease (AD). LY2062430 (solanezumab) is a humanized monoclonal antibody being studied as a putative disease-modifying treatment of AD.; Methods: Patients with mild to moderate AD were screened and selected for inclusion. Initial screening was performed for 54 subjects, […]
Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease
Chen, Y.,
Wolk, D. A.,
Reddin, J. S.,
Korczykowski, M.,
Martinez, P. M.,
Musiek, E. S.,
Newberg, A. B.,
Julin, P.,
Arnold, S. E.,
Greenberg, J. H.,
Detre, J. A.
Objective: We compared the ability of arterial spin labeling (ASL), an MRI method that measures cerebral blood flow (CBF), to that of FDG-PET in distinguishing patients with Alzheimer disease (AD) from healthy, age-matched controls.; Methods: Fifteen patients with AD (mean age 72 ± 6 years, Mini-Mental State Examination score [MMSE] 20 ± 6) and 19 […]
Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment
Bayer-Carter, Jennifer L.,
Green, Pattie S.,
Montine, Thomas J.,
VanFossen, Brian,
Baker, Laura D.,
Watson, G. Stennis,
Bonner, Laura M.,
Callaghan, Maureen,
Leverenz, James B.,
Walter, Brooke K.,
Tsai, Elaine,
Plymate, Stephen R.,
Postupna, Nadia,
Wilkinson, Charles W.,
Zhang, Jing,
Lampe, Johanna,
Kahn, Steven E.,
Craft, Suzanne
Objective: To compare the effects of a 4-week high-saturated fat/high-glycemic index (HIGH) diet with a low-saturated fat/low-glycemic index (LOW) diet on insulin and lipid metabolism, cerebrospinal fluid (CSF) markers of Alzheimer disease, and cognition for healthy adults and adults with amnestic mild cognitive impairment (aMCI).; Design: Randomized controlled trial.; Setting: Veterans Affairs Medical Center clinical […]
A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease
Objectives: To evaluate the safety of the peroxisome proliferator-activated receptor gamma agonist pioglitazone in nondiabetic patients with Alzheimer disease (AD) and to explore treatment effect sizes on clinical outcomes.; Design: Double-blind, placebo-controlled randomized controlled trial of 18-month duration.; Setting: Two academic medical center outpatient clinics.; Patients: Nondiabetic patients meeting research criteria for probable AD were […]
Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers
Serrano-Pozo, Alberto,
Vega, Gloria L.,
Lütjohann, Dieter,
Locascio, Joseph J.,
Tennis, Marsha K.,
Deng, Amy,
Atri, Alireza,
Hyman, Bradley T.,
Irizarry, Michael C.,
Growdon, John H.
Preclinical and epidemiologic studies suggest a protective effect of statins on Alzheimer disease (AD). Experimental evidence indicates that some statins can cross the blood-brain barrier, alter brain cholesterol metabolism, and may ultimately decrease the production of amyloid-beta (Abeta) peptide. Despite these promising leads, clinical trials have yielded inconsistent results regarding the benefits of statin treatment […]
Cognition and function in Alzheimer’s disease: identifying the transitions from moderate to severe disease
Background/aims: Cognitive and functional decline define the transition from moderate to severe Alzheimer’s disease (AD); however, specific relationships between deteriorating cognition and functional abilities are less well characterized. Such relationships are important in care planning and understanding patient needs. Objectives of this post hoc analysis of data from a multicenter randomized double-blind placebo-controlled study were […]